Neogenomics (NEO) PT Raised to $13 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NEO Hot Sheet
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Jefferies analyst Tycho Peterson raised the price target on Neogenomics (NASDAQ: NEO) to $13.00 (from $7.50) while maintaining a Buy rating.
The analyst comments "NEO posted a modest beat (+2%), underpinned by solid clinical and NGS momentum, which is a constructive pivot following back-to-back misses. FY25 guidance was reaffirmed. Looking to 2026, we see a favorable setup, aided by MRD expansion (sign up for our upcoming MRD call here), the PanTracer LBx rollout, and operational streamlining as key growth levers. Reiterate Buy. "
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- CG Power & Industrial Solutions (CGPOWER:IN) PT Raised to INR944 at JPMorgan
- Hindustan Petroleum (HPCL:IN) PT Lowered to INR350 at Kotak
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Jefferies & Co, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
